Published in Pharmacotherapy on April 18, 2013
Managing a Rivaroxaban Bleed: Understanding the Difficulties in Acute Reversal of the New Oral Anticoagulants through a Case Report. Case Rep Hematol (2014) 0.75
In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates. Blood Transfus (2016) 0.75
New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World J Orthop (2014) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature (2004) 5.95
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med (2009) 5.48
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med (1996) 3.86
Neurosurgical complications of direct thrombin inhibitors--catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran. J Neurosurg (2012) 3.84
The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med (1996) 3.79
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest (2001) 3.64
Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med (2000) 3.60
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol (2007) 3.09
Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost (2010) 3.03
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med (2002) 2.85
Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet (2010) 2.65
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost (2012) 2.61
The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem (1974) 2.59
Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med (1996) 2.50
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos (2007) 2.47
Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects. Eur J Clin Pharmacol (2005) 2.40
National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes (2012) 2.27
Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol (2008) 2.27
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost (2005) 2.16
Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med (2002) 1.95
Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res (2005) 1.91
Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest (2005) 1.90
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 1.85
How factor VIIa works in hemophilia. J Thromb Haemost (2003) 1.81
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol (2010) 1.71
Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet (2008) 1.71
A prospective randomized study to determine the optimal dose of intravenous vitamin K in reversal of over-warfarinization. Br J Haematol (2000) 1.70
Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med (2001) 1.69
Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother (2011) 1.69
Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc (2007) 1.66
Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet (1979) 1.66
Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry (1978) 1.63
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood (2012) 1.59
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol (2005) 1.58
Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med (2000) 1.55
In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost (2007) 1.54
Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. Drug Metab Dispos (2009) 1.53
Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke (1992) 1.48
Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost (1997) 1.41
Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med (1995) 1.34
Prothrombin complex concentrates: an update. Blood Transfus (2010) 1.27
Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery (1999) 1.27
Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang (2010) 1.21
Anticoagulants and their reversal. Transfus Med Rev (2007) 1.18
Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion (2009) 1.17
Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc (2004) 1.15
Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother (2012) 1.14
Emergency reversal of anticoagulation with a three-factor prothrombin complex concentrate in patients with intracranial haemorrhage. Blood Transfus (2011) 1.14
Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg (2000) 1.13
Clinical challenges in a patient with dabigatran-induced fatal hemorrhage. Am J Geriatr Pharmacother (2012) 1.12
New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol (2011) 1.11
Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med (2003) 1.07
Reversal of antithrombotic agents. Am J Hematol (2012) 1.05
Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents. J Thromb Haemost (2009) 1.05
In vitro metabolism of rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans. Drug Metab Dispos (2009) 1.04
Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature review. Int J Emerg Med (2011) 1.01
A spectrum of partially carboxylated prothrombins in the plasmas of coumarin-treated patients. Biochim Biophys Acta (1977) 0.99
The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg (2003) 0.99
Epidural hematoma and intraoperative hemorrhage in a spine trauma patient on Pradaxa (dabigatran). Spine (Phila Pa 1976) (2012) 0.98
Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage. J Neurosurg (2011) 0.91
Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis (2001) 0.90
Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. Eur J Haematol (2006) 0.87
Warfarin reversal emerging as the major indication for fresh frozen plasma use at a tertiary care hospital. Am J Hematol (2007) 0.87
Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med (2000) 0.85
How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood (2011) 0.84
Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR>10. Thromb Res (2004) 0.83
A survey of oral vitamin K use by anticoagulation clinics. Arch Intern Med (2002) 0.83
Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio. Chest (2003) 0.83
Treatment of warfarin-associated coagulopathy with vitamin K. Expert Rev Hematol (2011) 0.82
Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med (2011) 0.82
Comparison of the efficacy and safety profiles of intravenous vitamin K and fresh frozen plasma as treatment of warfarin-related over-anticoagulation in patients with mechanical heart valves. Am J Cardiol (2005) 0.81
Urgent reversal of vitamin K antagonist therapy. Acta Anaesthesiol Scand (2011) 0.81
Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10. Results of a prospective cohort study. Thromb Haemost (2010) 0.81
Vitamin K epoxide reductase complex subunit 1 (VKORC1 ) polymorphism influences the anticoagulation response subsequent to vitamin K intake: a pilot study. J Thromb Haemost (2008) 0.80
Prothrombin complex concentrates used alone in urgent reversal of warfarin anticoagulation. Intern Med J (2011) 0.79
Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. Blood Transfus (2011) 0.79
Retrospective and prospective analyses of the treatment of overanticoagulated patients. Pharmacotherapy (1999) 0.79
Retrospective evaluation of a method to predict fresh-frozen plasma dosage in anticoagulated patients. Am J Ther (2008) 0.78
Dosing of 3-factor prothrombin complex concentrate for international normalized ratio reversal. Ann Pharmacother (2011) 0.76
Prothrombin complex concentrates to reverse warfarin-related bleeding. Med Lett Drugs Ther (2011) 0.75
Reversal of warfarin-induced over-anticoagulation with individualized dosing of oral vitamin K: a pilot study. J Thromb Haemost (2010) 0.75
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy. Thromb Haemost (2011) 1.35
Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics. Pharmacogenomics (2008) 1.14
Prevalence and correlates of low medication adherence in apparent treatment-resistant hypertension. J Clin Hypertens (Greenwich) (2012) 1.10
Hyperammonemia following intravenous valproate loading. Epilepsy Res (2009) 1.00
High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans. Bioinformatics (2011) 0.95
Warfarin pharmacogenomics. Curr Opin Mol Ther (2009) 0.94
Pathway analysis of genome-wide data improves warfarin dose prediction. BMC Genomics (2013) 0.87
Influence of kidney function on risk of hemorrhage among patients taking warfarin: a cohort study. Am J Kidney Dis (2012) 0.87
Controlling Population Structure in Human Genetic Association Studies with Samples of Unrelated Individuals. Stat Interface (2011) 0.84
Admixture Mapping of Subclinical Atherosclerosis and Subsequent Clinical Events Among African Americans in 2 Large Cohort Studies. Circ Cardiovasc Genet (2017) 0.80
Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications. Pharmacotherapy (2014) 0.78
Predictors of Thromboembolic Events in Patients with Ventricular Assist Device. ASAIO J (2015) 0.78
Vitamin K intake, body mass index and warfarin maintenance dose. Cardiology (2013) 0.77
Use of secondary prevention medications among adults with reduced kidney function. Clin J Am Soc Nephrol (2012) 0.77
A systematic analysis and comparison of warfarin initiation strategies. Pharmacogenet Genomics (2016) 0.75
Anticoagulation Control in Patients With Ventricular Assist Devices. ASAIO J (2017) 0.75